TRT and cardiovascular health: What the research says

Written by Adam Maggio | Medically reviewed by Dr. Mitchell Ross, MD, ABAARM

# TRT and Cardiovascular Health: What the Research Really Says

Summary:

Testosterone Replacement Therapy (TRT) is commonly used to treat low testosterone, but its impact on cardiovascular health remains debated. This article reviews current evidence, dosing protocols, and safety considerations.

Tags:

TRT, testosterone replacement therapy, cardiovascular health, heart disease, hormone therapy, dosing protocols, men's health, peptide therapy

---

Understanding TRT and Cardiovascular Health

Testosterone Replacement Therapy (TRT) is a well-established treatment for men with clinically low testosterone levels, often improving symptoms such as fatigue, low libido, and muscle loss. However, concerns about TRT’s impact on cardiovascular health have generated significant debate in both medical and patient communities. Some fear that TRT may increase the risk of heart attacks, strokes, or other cardiovascular events, while emerging research suggests it may have neutral or even protective effects when properly managed.

This article explores what current scientific literature reveals about TRT and cardiovascular risk, practical protocols for safe use, and important considerations for patients and healthcare providers alike.

---

What Does the Research Say?

Cardiovascular Risks: Conflicting Data

Early observational studies and some retrospective analyses suggested an increased risk of cardiovascular events among men on TRT. For example, a 2013 study in JAMA reported higher rates of heart attacks and strokes in men prescribed testosterone, raising alarms. However, these studies often had limitations, such as selection bias or confounding variables.

More recent randomized controlled trials (RCTs) and meta-analyses provide a more nuanced view:

  • A 2020 systematic review and meta-analysis published in The Lancet Diabetes & Endocrinology examined over 3,000 men and found no significant increase in major adverse cardiovascular events (MACE) with TRT compared to placebo.
  • The TRAVERSE trial (ongoing) is a large-scale RCT specifically designed to evaluate TRT’s cardiovascular safety in hypogonadal men with increased cardiovascular risk. Preliminary data have not shown increased risk, but final results are pending.
  • Some studies even suggest TRT may improve cardiovascular markers by reducing fat mass, improving insulin sensitivity, and enhancing endothelial function.

    • Mechanisms of Cardiovascular Effects

    Testosterone influences cardiovascular health through multiple pathways:

  • Positive effects: TRT can improve body composition (increase lean mass, reduce fat), enhance lipid profiles (increase HDL cholesterol), and improve insulin resistance — all of which may reduce cardiovascular risk.
  • Potential negative effects: TRT may increase hematocrit (red blood cell concentration), which could theoretically raise the risk of thrombosis if not monitored. It may also affect blood pressure and fluid retention in some individuals.

    • Proper patient selection and monitoring are key to minimizing risks.

    ---

    Practical TRT Protocols for Cardiovascular Safety

    Patient Selection

  • Confirm low testosterone levels with at least two morning serum testosterone measurements.
  • Evaluate cardiovascular risk factors: history of heart disease, stroke, hypertension, diabetes, smoking status.
  • Consider age and comorbidities — older men or those with existing cardiovascular disease require more cautious assessment.

    • Dosing Recommendations

    TRT dosing varies by formulation (injections, gels, patches). Common dosing protocols include:

  • Testosterone injections (e.g., testosterone cypionate or enanthate): 50-100 mg intramuscularly weekly or 100-200 mg every two weeks.
  • Testosterone gels: 5-10 grams applied daily delivering approximately 50-100 mg testosterone.
  • Testosterone patches: Applied daily as per manufacturer instructions.

    • The goal is to maintain serum testosterone in the mid-normal range (typically 400-700 ng/dL), avoiding supraphysiologic levels that may increase risk.

    Monitoring Protocols

  • Check serum testosterone levels 2-4 weeks after initiation and periodically thereafter.
  • Monitor hematocrit every 3-6 months. If hematocrit exceeds 54%, dose reduction or therapeutic phlebotomy may be necessary.
  • Regularly assess blood pressure, lipid profile, and cardiovascular symptoms.
  • Evaluate prostate-specific antigen (PSA) and digital rectal exams per standard guidelines.

    • Lifestyle and Adjunctive Measures

  • Encourage heart-healthy lifestyle: balanced diet, regular exercise, smoking cessation.
  • Manage comorbidities such as hypertension, diabetes, and dyslipidemia aggressively.
  • Consider anticoagulation if indicated, especially in patients with elevated hematocrit or thrombotic risk.

    • ---

    Evidence-Based Benefits of TRT on Cardiovascular Markers

    Several studies have demonstrated that when appropriately prescribed and monitored, TRT can confer cardiovascular benefits:

  • Improved insulin sensitivity: TRT has been shown to reduce fasting glucose and improve HbA1c in men with type 2 diabetes.
  • Reduced fat mass: Testosterone increases lean body mass and decreases visceral fat, a known risk factor for cardiovascular disease.
  • Enhanced endothelial function: Some trials report improved arterial stiffness and flow-mediated dilation after TRT.

    • These benefits are dose-dependent and require maintaining physiological testosterone levels.

    ---

    Important Precautions and When to Avoid TRT

  • TRT is not recommended for men with active prostate cancer or breast cancer.
  • Use cautiously or avoid in men with recent (within 6 months) myocardial infarction or stroke until more data are available.
  • Avoid supraphysiologic dosing or “stacking” with anabolic steroids, which significantly increases cardiovascular risks.
  • Always consult a healthcare provider before starting or adjusting TRT.

    • ---

    Conclusion

    The relationship between Testosterone Replacement Therapy and cardiovascular health is complex and evolving. While early studies raised concerns about increased cardiovascular risk, more recent high-quality research suggests that TRT, when appropriately prescribed and monitored, does not increase—and may even improve—cardiovascular outcomes in men with low testosterone.

    Key to safe TRT use is thorough patient evaluation, individualized dosing to maintain physiological testosterone levels, and ongoing monitoring of cardiovascular markers including hematocrit and lipid profiles. Patients should always engage with knowledgeable healthcare providers to ensure therapy is tailored to their health status and risk profile.

    By balancing benefits and risks, TRT can be a valuable tool in improving quality of life and potentially cardiovascular health in men with hypogonadism.

    ---

    Disclaimer: This article is for informational purposes only and does not replace professional medical advice. Always consult your healthcare provider before starting or modifying any hormone therapy.